Chemotherapy with Phage Lysins Reduces Pneumococcal Colonization of the Respiratory Tract

Antimicrob Agents Chemother. 2018 May 25;62(6):e02212-17. doi: 10.1128/AAC.02212-17. Print 2018 Jun.

Abstract

Bacteriophage-borne lytic enzymes, also named lysins or enzybiotics, are efficient agents for the killing of bacterial pathogens. The colonization of the respiratory tract by Streptococcus pneumoniae is a prerequisite for the establishment of the infection process. Hence, we have evaluated the antibacterial activities of three different lysins against pneumococcal colonization using human nasopharyngeal and lung epithelial cells as well as a mouse model of nasopharyngeal colonization. The lysins tested were the wild-type Cpl-1, the engineered Cpl-7S, and the chimera Cpl-711. Moreover, we included amoxicillin as a comparator antibiotic. Human epithelial cells were infected with three different multidrug-resistant clinical isolates of S. pneumoniae followed by a single dose of the corresponding lysin. The antimicrobial activities of these lysins were also evaluated using a mouse nasopharyngeal carriage model. The exposure of the infected epithelial cells to Cpl-7S did not result in the killing of any of the pneumococcal strains investigated. However, the treatment with Cpl-1 or Cpl-711 increased the killing of S. pneumoniae organisms adhered to both types of human epithelial cells, with Cpl-711 being more effective than Cpl-1, at subinhibitory concentrations. In addition, a treatment with amoxicillin had no effect on reducing the carrier state, whereas mice treated by the intranasal route with Cpl-711 showed significantly reduced nasopharyngeal colonization, with no detection of bacterial load in 20 to 40% of the mice. This study indicates that Cpl-1 and Cpl-711 lysins might be promising antimicrobial candidates for therapy against pneumococcal colonization.

Keywords: mouse model; nasopharyngeal colonization; phage lysins; pneumococcus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Humans
  • Mice
  • Nasopharyngeal Diseases / drug therapy
  • Nasopharyngeal Diseases / microbiology*
  • Pneumococcal Infections / drug therapy
  • Pneumococcal Infections / microbiology*
  • Respiratory System / microbiology*
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / pathogenicity*

Substances

  • Anti-Bacterial Agents